Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138198 | 0.76 | SLC5A2 (0.35) | SLC5A2SLC5A1TERT | |
| SCHEMBL20138262 | 0.76 | MAPK1 (0.37) | SLC5A2SLC5A1 | |
| SCHEMBL20138003 | 0.68 | SLC5A2 (0.33) | SLC5A2SLC5A1 | |
| SCHEMBL20137997 | 0.67 | TSHR (0.37) | — | |
| SCHEMBL20137924 | 0.65 | BRD4 (0.35) | — | |
| SCHEMBL20138084 | 0.62 | TSHR (0.35) | — | |
| SCHEMBL20137985 | 0.61 | ALDH1A1 (0.32) | — | |
| SCHEMBL20137971 | 0.61 | SMN1; SMN2 (0.36) | SLC5A2SLC5A1TERT | |
| SCHEMBL9838053 | 0.58 | HTR6 (0.49) | — | |
| SCHEMBL1334990 | 0.58 | PDE3B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | SLC5A2 2150/4885SLC5A1 1345/4885TERT 4230/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | SLC5A2 3396/4885SLC5A1 2429/4885TERT 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.